183 related articles for article (PubMed ID: 8468725)
1. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
[TBL] [Abstract][Full Text] [Related]
2. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
3. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
4. Contribution of de-novo and salvage synthesis to the uracil nucleotide pool in mouse tissues and tumors in vivo.
Zaharevitz DW; Anderson LW; Malinowski NM; Hyman R; Strong JM; Cysyk RL
Eur J Biochem; 1992 Nov; 210(1):293-6. PubMed ID: 1446677
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
7. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
8. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
9. The role of low-dose PALA in biochemical modulation.
O'Dwyer PJ
Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
[TBL] [Abstract][Full Text] [Related]
10. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Karle JM; Cowan KH; Chisena CA; Cysyk RL
Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
[TBL] [Abstract][Full Text] [Related]
11. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
12. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Karle JM; Anderson LW; Dietrick DD; Cysyk RL
Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of uracil nucleotide synthesis in mouse liver, intestine and kidney by ammonium chloride infusion.
Zaharevitz DW; Napier EA; Anderson LW; Strong JM; Cysyk RL
Eur J Biochem; 1988 Jul; 175(1):193-8. PubMed ID: 3402448
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
15. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
16. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
17. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
[TBL] [Abstract][Full Text] [Related]
18. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Martin DS; Kemeny NE
Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
[TBL] [Abstract][Full Text] [Related]
19. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper ES; Vale K; Williams LJ; Martin DS; Young CW
Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based model for tumor drug resistance.
Kuczek T; Chan TC
Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]